// App-Quantinova.ai

OT1-08-06 : International, phase 3 trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS) international, phase 3 trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS)

Researchers

Presenter

  • Peter Kaufmann

Principal Investigators

  • Javier Cortes

  • Miguel Martin

  • Ingrid Mayer

  • Linda Vahdat

  • Sonia Pernas

  • Peter Schmid

  • Heather McArthur

  • Rebecca Dent

  • Hope Rugo

  • Carlos Barrios

  • Debra Barker

  • Barbara Romagnoli

  • Alexandra Bobirca

Medical Centers

  • University of Vermont Medical Center, Burlington, VT

  • Ramon y Cajal University Hospital, Madrid, Spain

  • Hospital Universitario Quiron Madrid, Madrid, Spain

  • Vanderbilt University Medical Center, Nashville, TN

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • ICO Institut Catala d'Oncologia, Barcelona, Spain

  • Queen Mary University of London, London, United Kingdom

  • Cedar-Sinai, Los Angeles, CA

  • National Cancer Centre Singapore, Singapore, Singapore

  • University of California, San Francisco, San Francisco, CA

  • Hospital do Câncer Mãe de Deus Centro de Pesquisa Clínica Hospital São Lucas, Porto Alegre, Brazil

  • Polyphor Ltd, Allschwil, Switzerland

Locations

  • United States

  • Spain

  • United Kingdom

  • Singapore

  • Brazil

  • Switzerland

Companies

  • Polyphor Ltd.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Squamous cell carcinoma

  • Cervical cancer

  • Skin carcinoma

  • Solid malignancies

Biomarkers

  • Progesterone receptor

  • C-X-C motif chemokine receptor 4

  • erb-b2 receptor tyrosine kinase 2

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Eribulin

  • taxane

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multiple Arm

  • Multinational

  • Multicenteric

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved